The intrauterine contraceptive device: An often-forgotten and maligned method of contraception

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 1, 1999, Pages 1-5

  Dardano, Kristin L ^a   Burkman, Ronald T ^a  

^a NONE

Author keywords

Candidates for use; Intrauterine contraceptive device; Levonorgestrel releasing intrauterine contraceptive device; Mechanism of action; Pelvic inflammatory disease

Indexed keywords

BARIUM SULFATE; COPPER INTRAUTERINE DEVICE; GESTAGEN; LEVONORGESTREL; POLYETHYLENE; PROGESTERONE;

AGE; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; ENDOMETRIUM ABLATION; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE DRUG ADMINISTRATION; MENORRHAGIA; ORAL DRUG ADMINISTRATION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0032870670     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70426-6     Document Type: Article

References (25)

1. 1. Abma JC, Chandra A, Mosher WD, Peterson LS, Piccinino LJ. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth, National Center for Health Statistics. Vital Health Stat 23 1997;19:1-114.
2. 2. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-7.
3. 3. Ortiz ME, Croxalto HB, Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv 1996;51 Suppl:S42-51.
4. 4. Hagenfeldt K. Intrauterine contraception with the copper-T device: effect on trace elements in the endometrium, cervical mucus and plasma. Contraception 1972;6:37-54.
5. 5. Ullmann G, Hammerstein J. Inhibition of sperm motility in vitro by copper wire. Contraception 1972;6:71-6.
6. 6. Tredway DR, Umezaki CU, Mishell DR Jr, Settlage DS. Effect of intrauterine devices on sperm transport in the human being: preliminary report. Am J Obstet Gynecol 1975;123:734-5.
7. 7. Sivin I. IUDs are contraceptives, not abortifacients: a comment on research and belief. Stud Fam Plann 1989;20:355-9.
8. 8. Alvarez F, Brache V, Fernandez E, Guerrero B, Guiloff E, Hess R, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988;49:768-73.
9. 9. Sagiroglu N. Phagocytosis of spermatozoa in the uterine cavity of woman using intrauterine device. Int J Fertil 1971;16:1-14.
10. 10. Wilcox AJ, Weinberg CR, Armstrong EG, Canfield RE. Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay. Fertil Steril 1987;47:265-9.
11. 11. Mastroianni L Jr. No evidence to support intrauterine contraceptive device and embryo destruction [letter]. Am J Obstet Gynecol 1997;177:980.
12. 12. Burkmann RT. Intrauterine devices and pelvic inflammatory disease: evolving perspectives on the data. Obstet Gynecol Surv 1996;51:S35-41.
13. 13. Skjeldestad FF., How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet Gynecol Scand 1997;76:684-90.
14. 14. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 1998;351:1238-41.
15. 15. Treiman K, Liskin L, Kols A, Rinchart W. IUDs: an update. Baltimore: Johns Hopkins School of Public Health, Population Information Program; 1995. p. 1-35.
16. 16. Coleman M, McCowan L, Farquhar C. The levonorgestrel-releasing intrauterine device: a wider role than contraception. Aust N Z J Obstet Gynaecol 1997;37:195-201.
17. 17. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-9.
18. 18. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-63.
19. 19. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-7.
20. 20. Duenas JL, Albert A, Carrasco F. Intrauterine contraception in nulligravid vs parous women. Contraception 1996;53:23-4.
21. 21. Mishell DR, Roy S. Copper intrauterine contraceptive device rates following insertion 4 to 8 weeks post partum. Am J Obstet Gynecol 1982;143:29-33.
22. 22. Farr G, Rivera R. Interactions between intrauterine contraceptive device use and breast-feeding status at time of intrauterine contraceptive device insertion: analysis of TCu-380A acceptors in developing countries. Am J Obstet Gynecol 1992;167:144-51.
23. 23. Chi IC, Jones DB. Incidence, risk factors, and prevention of poststerilization regret in women: an updated international review from an epidemiologic perspective. Obstet Gynecol Surv 1994;49:722-35.
24. 24. Mestman JH, Schmidt-Sarosi C. Diabetes mellitus and fertility control: contraception management issues. Am J Obstet Gynecol 1993;168:2012-8.
25. 25. Skouby SO, Mølsted-Pedersen L, Kosonen A. Consequences of intrauterine contraception in diabetic women. Fertil Steril 1984;42:568-72.